{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:07:30Z","timestamp":1767136050010,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd010455","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T00:00:00Z","timestamp":1411948800000}}],"reference-count":71,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010455.pub2","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T12:40:04Z","timestamp":1411994404000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity"],"prefix":"10.1002","author":[{"given":"Noortje","family":"van Herwaarden","sequence":"first","affiliation":[{"name":"Sint Maartenskliniek; Department of Rheumatology; Hengstdal 3 Nijmegen Gelderland Netherlands 6522 JV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfons A","family":"den Broeder","sequence":"additional","affiliation":[{"name":"Sint Maartenskliniek; Department of Rheumatology; Hengstdal 3 Nijmegen Gelderland Netherlands 6522 JV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilco","family":"Jacobs","sequence":"additional","affiliation":[{"name":"The Health Scientist; Fraeylemastraat 13 The Hague Netherlands 2532 TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aatke","family":"van der Maas","sequence":"additional","affiliation":[{"name":"Sint Maartenskliniek; Department of Rheumatology; Hengstdal 3 Nijmegen Gelderland Netherlands 6522 JV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes WJ","family":"Bijlsma","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht; Rheumatology & Clinical Immunology; Box 85 500 3508 GA Utrecht Netherlands 3508 GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[{"name":"The Karolinska Institute; Department of Medicine; Avdelning D1:00 Stockholm Stockholm Sweden 17176"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartholomeus JF","family":"van den Bemt","sequence":"additional","affiliation":[{"name":"Sint Maartenskliniek; Department of Pharmacy; Hengstdal 3 Nijmegen Gelderland Netherlands 6522JV"},{"name":"Radboud University Medical Center; Department of Pharmacy; Nijmegen Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,29]]},"reference":[{"key":"10.1002\/14651858.CD010455.pub2-BIB0001|cit1","first-page":"54","article-title":"Effects of low-dose etanercept in maintaining DAS-remission previously achieved with standard-dose in patients with rheumatoid arthritis","volume":"66(Suppl II)","author":"Botsios","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0002|cit2","first-page":"776","article-title":"Multicenter, randomised, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission","volume":"64(Suppl 10)","author":"Chatzidionysiou","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0003|cit3","first-page":"262","article-title":"Maintenance of biologic-free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate","volume":"70 (Suppl 3)","author":"Emery","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD010455.pub2-BIB0004|cit4","first-page":"4169","article-title":"Tapering TNF-blockers in established rheumatoid arthritis patients in DAS28 remission: results of a DAS28-driven step-down strategy randomized controlled trial","volume":"64","author":"Fautrel","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3109\/s10165-011-0586-5","article-title":"Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity","volume":"22","author":"Harigai","year":"2012","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD010455.pub2-BIB0007|cit7","first-page":"4171","article-title":"Rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-armed, double-blind clinical trial","volume":"64","author":"Vollenhoven","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrrheum.2010.101","article-title":"Challenging the course of RA: time for drug-free remission?","volume":"6","author":"Aletaha","year":"2010","journal-title":"Nature Reviews Rheumatology"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0009|cit9","article-title":"Sustained remission at 6 months, despite reduction in anti-TNF dosing frequency in inflammatory arthritis","volume":"181(Suppl 2)","author":"Awan","year":"2011","journal-title":"Irish Journal of Medical Science"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/rheumatology\/keq194","article-title":"Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis","volume":"49","author":"Bejarano","year":"2010","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/annrheumdis-2012-201612","article-title":"Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-na\u00efve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study","volume":"72","author":"Detert","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Emery P Hammoudeh M FitzGerald O Combe B Martin Mola E Bukowski J Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study Annals of the Rheumatic Diseases 2013 399","DOI":"10.1136\/annrheumdis-2013-eular.1216"},{"issue":"7","key":"10.1002\/14651858.CD010455.pub2-BIB0013|cit13","first-page":"1293","article-title":"Maintenance therapy for rheumatoid arthritis after remission following successful treatment using biologics","volume":"65","author":"Ichikawa","year":"2007","journal-title":"Nihon Rinsho"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0014|cit14","first-page":"S200","article-title":"Role of infliximab in the treatment of early rheumatoid arthritis","volume":"21(Suppl 31)","author":"Keystone","year":"2003","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/ard.2010.136556","article-title":"Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD010455.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S0266462311000195","article-title":"Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment","volume":"27","author":"Kobelt","year":"2011","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"1","key":"10.1002\/14651858.CD010455.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","article-title":"Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial","volume":"52","author":"Quinn","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0018|cit18","first-page":"25","article-title":"Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from the certain study","volume":"71(Suppl 3)","author":"Smolen","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/rheumatology\/kes188","article-title":"Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study","volume":"51","author":"Tada","year":"2012","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/ard.2010.147751","article-title":"Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study","volume":"70","author":"Broek","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/ard.2008.092254","article-title":"Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis","volume":"68","author":"Kooij","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0022|cit22","first-page":"2465","article-title":"Preliminary results of a multicentre randomised controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis","volume":"63(Suppl 10)","author":"Villeneuve","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0023|cit23","unstructured":"Remission in rheumatoid arthritis-Assessing withdrawal of disease-modifying antirheumatic drugs in a non-inferiority design Ongoing study June 2013"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0024|cit24","unstructured":"Randomised controlled non-inferiority study of dose reduction and withdrawal strategies of adalimumab and etanercept in rheumatoid arthritis: saving costs at what expense? Ongoing study December 2011"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0025|cit25","unstructured":"Potential optimalisation (expediency) and effectiveness of TNF-blockers Ongoing study October 2011"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0026|cit26","unstructured":"Reduction of therapy in patients with RA in ongoing remission Ongoing study"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0027|cit27","unstructured":"Stopping tumor necrosis factor-alpha inhibitors in rheumatoid arthritis Ongoing study January 2013"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0028|cit28","unstructured":"Dose-to-target of etanercept treatment: a dose-tapering randomised controlled trial in patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis Ongoing study May 2013"},{"issue":"Suppl. 39","key":"10.1002\/14651858.CD010455.pub2-BIB0029|cit29","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD010455.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD010455.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD010455.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD010455.pub2-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003785","article-title":"Infliximab for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010455.pub2-BIB0034|cit34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004525","article-title":"Etanercept for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"19","key":"10.1002\/14651858.CD010455.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomised controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD010455.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jbspin.2008.11.009","article-title":"Effect of discontinuing TNFa antagonist therapy in patients with remission of rheumatoid arthritis","volume":"76","author":"Brocq","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1002\/14651858.CD010455.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/rheumatology\/41.6.638","article-title":"Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-\u03b1","volume":"41","author":"Broeder","year":"2002","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD010455.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/rheumatology\/keq060","article-title":"Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA","volume":"49","author":"Broeder","year":"2010","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD010455.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.joca.2009.03.023","article-title":"The \u2018placebo\u2019 response in osteoarthritis and its implications for clinical practice","volume":"17","author":"Doherty","year":"2009","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/annrheumdis-2013-eular.271","article-title":"Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step-down strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial)","volume":"72(Suppl 3)","author":"Fautrel","year":"2013","journal-title":"Annals of Rheumatic Disease"},{"issue":"3","key":"10.1002\/14651858.CD010455.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"5 Suppl 39","key":"10.1002\/14651858.CD010455.pub2-BIB0042|cit42","first-page":"S93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clinical Experimental Rheumatology"},{"issue":"7414","key":"10.1002\/14651858.CD010455.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0044|cit44","unstructured":"Higgins JPT Green S (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/annrheumdis-2012-eular.450","article-title":"Effect of adalimumab discontinuation on patient-reported outcomes and work productivity in early rheumatoid arthritis patients who achieved low disease activity following 26 weeks of treatment:data from the OPTIMA study","volume":"71(Suppl 3)","author":"Kavanaugh","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD010455.pub2-BIB0046|cit46","first-page":"238","article-title":"Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis","volume":"29","author":"Klareskog","year":"2011","journal-title":"Clinical Experimental Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD010455.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/03009747509165261","article-title":"A radiological method for grading the severity of rheumatoid arthritis","volume":"4","author":"Larsen","year":"1973","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD010455.pub2-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005113.pub2","article-title":"Adalimumab for treating rheumatoid arthritis","author":"Navarro-Sarabia","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3109\/s10165-008-0089-1","article-title":"Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission","volume":"18","author":"Nawata","year":"2008","journal-title":"Modern Rheumatol"},{"issue":"1","key":"10.1002\/14651858.CD010455.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD010455.pub2-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007649.pub3","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","author":"Ruiz Garcia","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/ard.2009.117341","article-title":"Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?","volume":"69","author":"Saleem","year":"2010","journal-title":"Annals of Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD010455.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/art.1780140605","article-title":"Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD010455.pub2-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007848.pub2","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","author":"Singh","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010455.pub2-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008341","article-title":"Golimumab for rheumatoid arthritis","author":"Singh","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010455.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2012-eular.3081","article-title":"Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal od adalimumab (ADA) after achieving stable low disease activity with ADA plus methotrexate (MTX)-data from the OPTIMA study","volume":"71(Suppl 3)","author":"Smolen","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD010455.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"Clair","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD010455.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis:RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0060|cit60","first-page":"771","article-title":"Discontinuation of adalimumab without functional and radiographic damage progression after achieving sustained remission in patients with rheumatoid arthritis (the HONOR study): 1-year results","volume":"64(Suppl 10)","author":"Tanaka","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD010455.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/ard.2007.083683","article-title":"Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study","volume":"67","author":"Bemt","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD010455.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/art.22718","article-title":"Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis","volume":"56","author":"Bijl","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD010455.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"Heijde","year":"1990","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD010455.pub2-BIB0064|cit64","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"Heijde","year":"2000","journal-title":"Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD010455.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1136\/annrheumdis-2011-200945","article-title":"Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment:an observational cohort study","volume":"71","author":"Maas","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/annrheumdis-2012-202281","article-title":"Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study","volume":"72","author":"Maas","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD010455.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/ard.2003.010967","article-title":"Dose escalation of infliximab in clinical practise: improvements seen may be explained by a regression-like effect","volume":"63","author":"Vollenhoven","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD010455.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1136\/ard.2009.111682","article-title":"How to dose infliximab in rheumatoid arthritis: new data on a serious issue","volume":"48","author":"Vollenhoven","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD010455.pub2-BIB0069|cit69","first-page":"501","article-title":"Minimal clinically important difference in radiological progression of joint damage. A definition based on patient perspective","volume":"33","author":"Welsing","year":"2006","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD010455.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010455.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2013-203302","article-title":"Biologic discontinuation studies: a systematic review of methods","volume":"73","author":"Yoshida","year":"2014","journal-title":"Annals of the Rheumatic Diseases"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010455.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010455.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T18:13:42Z","timestamp":1746382422000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010455.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,29]]},"references-count":71,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010455.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,29]]}}}